AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05225129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction exercise
Description: blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
Study NCT05381363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Interferon α2b
Description: Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
Study NCT05381363 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
Study NCT04485949 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IGV-001 Cell Immunotherapy
Description: IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
Study NCT04485949 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
Study NCT04485949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC): Radiation Therapy
Description: Radiation therapy administered per institutional standards.
Study NCT04485949 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC): Radiation Therapy
Description: Radiation therapy administered per institutional standards.
Study NCT05508100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108
Description: IO-108, intravenously, on Day 1 of each 21-day cycle.
Study NCT05508100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108 + pembrolizumab
Description: IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT05508100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-108 + tislelizumab
Description: IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT05745298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xcite Clinical Station
Description: The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
Study NCT06233253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT06233253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06233253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06233253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Meditation
Description: Receive an online mindfulness intervention
Study NCT06233253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06233253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05607914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percussion massage
Description: percussion massage to the dominant leg hamstring muscle for 5 minutes
Study NCT05607914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static stretching
Description: Static stretching to the dominant hamstring muscle for 5 minutes
Study NCT04988386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoramidis (AG10)
Description: Acoramidis (AG10) twice daily
Study NCT06297889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core strength training 1-6weeks
Description: Behaviour: core strength training intervention for 1-6 weeks. Experimental: The experimental group performed core strength training during weeks 1-3. Subjects were first provided with basic information, familiarised with the content of the first phase of core strength training and watched a core strength video to understand its importance. The initial intervention was designed to ensure that subjects were proficient in core strength training, including warm-up and stretching patterns. During weeks 4-6, subjects will be supervised and assisted and a test will be organised at the end of week 6. Variables related to physical fitness and skills were recorded to assess whether core strength training improved physical fitness and skills.
Study NCT06297889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core strength training 7-12weeks
Description: Behaviour: core strength training intervention #7-12 weeks#.~Experimental: Weeks 7-9 were the experimental group:~Continued to warm up before each training session. The training content will increase in difficulty during this phase, and the supervisor should explain the training content and watch videos of the movements prior to training and prepare the training equipment in advance to protect the athlete from injury. Weeks 10-12: This is an advanced stage, requiring equipment and difficult movements to complete, please supervisors to arrange personnel to do a good job of protection to ensure that the subjects can complete the training tasks. A test will be conducted the day after Week 12 to measure the athlete's physical fitness and skills.
Study NCT04751110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided rhomboid intercostal block
Description: A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
Study NCT06546813 — intervention group
Intervention type: OTHER
Intervention: scales and questionnaire administration
Description: evaluation of the quality of prosthetic intervention, verification of the adequacy of assistive devices, and outcomes measurement
Study NCT05169762 — intervention group
Intervention type: OTHER
Intervention: standard treatment
Description: starndard treatment for transgender women
Study NCT04719975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Fatigue (Stroop task)
Description: A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself.
Study NCT04719975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (Documentary)
Description: In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
Study NCT05684744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks
Study NCT05684744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
Study NCT04520490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
Study NCT04520490 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
Study NCT04520490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 mg [Bydureon]
Description: Weekly injections of active drug.
Study NCT04485949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC: Temozolomide
Description: Temozolomide administered orally.
Study NCT04485949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC: Temozolomide
Description: Temozolomide administered orally.
Study NCT06393075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined care guidance
Description: Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker
Study NCT06393075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general care guidance
Description: general care guidance
Study NCT04520490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly placebo injections
Study NCT01998074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed rice protein formula
Study NCT06500637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TB006
Description: TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
Study NCT06500637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
Study NCT04512794 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AcQMap High Resolution Imaging and Mapping System
Description: Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
Study NCT05702632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1- Reciprocal electrical stimulation
Description: A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
Study NCT05702632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraTogs orthotic treatment
Description: A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
Study NCT05702632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: Facilitation of balance and gait training
Study NCT05068141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
Study NCT05068141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle
Study NCT05614193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning imaging enhancement
Description: Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
Study NCT06326593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii aerobic training
Description: Nintendo Wii Fit Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character
Study NCT06326593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative chest care
Description: Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
Study NCT03222726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise group
Description: less than 6000 steps/day or 40,000 steps/week
Study NCT05200065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate
Description: Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
Study NCT05200065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar enucleation of the prostate
Description: Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
Study NCT06326593 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conservative chest care
Description: Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
Study NCT04490200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VESTA respirator
Description: The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
Study NCT04490200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional N95 respirator
Description: The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
Study NCT05084469 — intervention group
Intervention type: PROCEDURE
Intervention: PET-MRI in pain-free remission period
Description: Patients will performed PET-MRI scans. A first 30 minutes acquisition will be performed at time=60min after injection. A second 75 minutes acquisition will be performed at time=150min. Each scans will contain functional dynamic \[18F\]F13640 PET acquisition, anatomical and functional MRI images acquisition and pain evaluation using a score visual analogic scale.
Study NCT06143969 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound-assisted, catheter-directed thrombolysis
Description: After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
Study NCT05406167 — intervention group
Intervention type: DEVICE
Intervention: Registry - Observational
Description: Observation Registry for Medical Device
Study NCT06147908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW5221
Description: megestrol acetate
Study NCT06147908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW5221-R
Description: megestrol acetate
Study NCT05101967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Cervical Implant
Description: Cervical discectomy through anterior approach with replacement of disc by dynamic implant
Study NCT05101967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomt and Fusion
Description: Cervical discectomy through anterior approach with putting of cervical cage.
Study NCT04318847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: Administration of ondansetron 4 mg or 8 mg according to weight
Study NCT05769647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: 3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
Study NCT05769647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
Study NCT04723602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cAd3-Marburg
Description: A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
Study NCT04723602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cAd3-EBO-S
Description: A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
Study NCT05664464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
Study NCT05664464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
Study NCT05664464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
Study NCT05664464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
Study NCT05664464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
Study NCT05664464 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 30 x 2 Gy involved field radiotherapy with concomitant temozolomide
Study NCT05664464 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 30 x 2 Gy involved field radiotherapy with concomitant temozolomide
Study NCT06170268 — intervention group
Intervention type: OTHER
Intervention: Routine Care Documentation
Description: Routine Care Documentation